Hansa Biopharma to participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City
Lund, Sweden, May 13, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences:
The UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019, with a presentation at 10:00AM ET/ 4:00PM CET.
The 2019 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 21, 2019.
A live webcast of the UBS presentation will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com.
A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on March 13, 2019.
For further information, please contact:
Rolf Gulliksen, Head of Corporate Communications
Mobile: +46 (0) 733-328 634
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
Swedish Investor and Media Relations:
+46 70-311 99 60
U.S. Investor and Media Relations:
Stephanie Marks / David Rosen (media)
+1 212 600 1902
About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.